

Supplementary Table 8. Prevalence of *MET* tyrosine kinase domain (TKD) mutations across cancer types in cohort #2.

Cancer Type	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (N)	Oncogenic / likely oncogenic <i>MET</i> TKD mutations (%)	<i>MET</i> TKD mutations of unknown biological function (N)	<i>MET</i> TKD mutations of unknown biological function (%)	Total <i>MET</i> TKD mutations (N)	Total <i>MET</i> TKD mutations (%)	Total (N)
Melanoma	18	0.14	303	2.32	321	2.46	13,055
Other Skin Cancer	1	0.05	37	1.80	38	1.85	2,051
Renal Cancer	57	0.72	28	0.35	85	1.07	7,961
Uterine Cancer	7	0.04	113	0.72	120	0.76	15,767
Bladder Cancer	7	0.07	62	0.63	69	0.70	9,898
NSCLC	129	0.14	457	0.49	586	0.63	92,406
Other GI Cancer	4	0.06	34	0.52	38	0.59	6,478
Head And Neck Cancer	4	0.05	39	0.50	43	0.55	7,791
Colorectal Cancer	9	0.02	285	0.52	294	0.53	55,274
Prostate Cancer	4	0.02	136	0.51	140	0.53	26,503
Gastric Cancer	5	0.06	35	0.45	40	0.52	7,698
SCLC	3	0.06	23	0.44	26	0.50	5,186
CUP	21	0.09	97	0.41	118	0.50	23,771
Neuroendocrine Cancer	1	0.02	26	0.44	27	0.46	5,927
Brain Cancer	1	0.01	68	0.44	68	0.44	15,457
Sarcoma	0	0	5	0.36	5	0.36	1,406
Breast Cancer	3	0.01	170	0.35	173	0.36	48,675
Other Cancers*	5	0.03	52	0.30	57	0.32	17,625
Other Gynecologic Cancer	1	0.01	23	0.30	24	0.32	7,583
Esophageal Cancer	5	0.04	32	0.25	37	0.29	12,557
GU Others	0	0	4	0.28	4	0.28	1,447
Biliary Tract Cancer	1	0.01	33	0.26	34	0.26	12,894
Ovarian Cancer	5	0.02	59	0.23	64	0.25	25,783
Liver Cancer	1	0.04	5	0.21	6	0.25	2,433
Pancreatic Cancer	8	0.03	49	0.17	57	0.19	29,509
GIST	0	0	3	0.15	3	0.15	2,032

Abbreviations: CUP, cancer of unknown primary; HCC, hepatocellular carcinoma; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; GU, genitourinary; GIST, gastrointestinal stromal tumors; GI, gastrointestinal; NOS, not otherwise specified

*Other cancers are detailed in Supplementary Table 9.